More on CNXU
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $7.27 |
|
|||
| Open | $7.25 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $7.50 | ||||
| Day Low | $7.06 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 46,489 | ||||
- Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
- Conexeu to Present at 2026 Controversies & Conversations in Laser & Cosmetic Surgery Symposium on the Role of the Extracellular Matrix in Tissue Regeneration
- Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
- Form D Conexeu Sciences Inc.
- Form SCHEDULE 13G Conexeu Sciences Inc. Filed by: Wright Michael G.
- Form SCHEDULE 13G Conexeu Sciences Inc. Filed by: Paisley Capital Holdings Corp
- A Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Next
- The GLP-1s Are Creating Another Boom, a New $2 Billion Opportunity Exists in Aesthetics. Conexeu Is Building for It
- Form 8-K Conexeu Sciences Inc. For: Jul 07
- A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
Entities mentioned with CNXU
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Morgan Stanley | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- JPMorgan | View Related Stories »
- Show More...
